What long‑acting reversible contraceptive methods are recommended for obese patients?

Recommended Contraception for Obese Patients

Long-acting reversible contraceptives (LARCs)—specifically the levonorgestrel intrauterine device (IUD) and the etonogestrel subdermal implant—are the first-line contraceptive methods for obese patients, offering superior efficacy, minimal health risks, and important non-contraceptive benefits. 1

Why LARCs Are Preferred in Obesity

Superior Efficacy and Safety Profile

• The levonorgestrel IUD has a failure rate of less than 0.2% with typical use, making it one of the most effective contraceptive methods available regardless of body weight 1
• The etonogestrel implant has a failure rate of 0.05%, with no evidence of reduced effectiveness in obese women 1, 2
• Both methods avoid the pharmacokinetic concerns that affect oral contraceptives after bariatric surgery or in the setting of obesity-related metabolic changes 1, 3
• LARCs eliminate user-dependent adherence issues, which is critical since obesity does not reduce motivation but does increase pregnancy-related risks 1, 2

Avoidance of Estrogen-Related Risks

• Combined oral contraceptives containing estrogen should be avoided in obese patients because obesity itself is a relative contraindication due to increased venous thromboembolism risk 1, 4
• The levonorgestrel IUD contains no estrogen, making it suitable for obese women who have multiple cardiovascular risk factors 5
• Progestin-only methods (IUD and implant) carry minimal thrombotic risk compared to combined hormonal contraceptives 4, 3

Non-Contraceptive Benefits Particularly Relevant to Obesity

• The levonorgestrel IUD reduces heavy menstrual bleeding by 71-95%, a condition more prevalent in obese women 5, 6
• Levonorgestrel IUDs reduce the risk of endometrial cancer, which occurs at higher rates in obese populations 6
• Many women experience amenorrhea with the levonorgestrel IUD, which can be therapeutically beneficial 1, 5

Specific LARC Recommendations by Type

Levonorgestrel IUD Options

• Mirena (52 mg levonorgestrel): Approved for 5 years but effective for up to 7 years; ideal for women who also need treatment for heavy menstrual bleeding 1, 5
• Skyla (13.5 mg levonorgestrel): Approved for 3 years; smaller device that may be easier to insert, though not studied for heavy bleeding treatment 1, 5
• Liletta (52 mg levonorgestrel): Approved for 3 years; similar efficacy to Mirena 1, 5

Etonogestrel Implant (Nexplanon)

• Single-rod implant effective for 3 years with failure rate less than 1% 1
• Insertion is straightforward in the upper arm and not affected by body habitus 1
• Common reason for discontinuation is unpredictable bleeding, which should be discussed during counseling 1

Copper IUD (Paragard)

• The copper IUD is the most weight-neutral contraceptive option with no hormonal exposure and a 0.8% failure rate 1, 7
• Approved for 10 years of use, offering the longest duration of any reversible method 1
• May increase menstrual bleeding and cramping, making it less ideal for obese women who already have heavy menses 5

Methods to Avoid in Obese Patients

Combined Hormonal Contraceptives

• Combined oral contraceptives (COCs) increase venous thromboembolism risk when combined with obesity as an independent risk factor 1, 4
• The contraceptive patch may be less effective in obese women and carries the same estrogen-related risks 2
• After bariatric surgery, oral contraceptives may have reduced absorption due to anatomical changes in the gastrointestinal tract 1

Depot Medroxyprogesterone Acetate (DMPA)

• DMPA is consistently associated with the greatest weight gain among all contraceptive methods and should be avoided when weight is a concern 7
• Weight gain with DMPA averages 5-10 pounds in the first year, which is particularly problematic for obese patients 7

Practical Insertion Considerations

Addressing Provider Concerns

• Difficult IUD insertions occur in only 5% of cases and failed insertions in only 3%, with no significant difference across BMI groups 8
• Obesity does not increase IUD expulsion rates compared to normal-weight women 8
• Continuation rates for levonorgestrel IUDs are 76-80% at one year across all BMI categories 1, 8

Clinical Algorithm for LARC Selection in Obese Patients

Step 1: Assess for heavy menstrual bleeding

• If present → Recommend Mirena or Liletta (52 mg levonorgestrel IUD) for dual contraceptive and therapeutic benefit 5, 6
• If absent → Proceed to Step 2

Step 2: Assess patient preference for bleeding patterns

• If patient desires amenorrhea or minimal bleeding → Recommend levonorgestrel IUD (any dose) 5
• If patient prefers to maintain regular cycles → Recommend copper IUD 7

Step 3: Consider cardiovascular risk factors

• If multiple cardiovascular risk factors present → Strongly favor copper IUD (Category 1) over levonorgestrel IUD (Category 2) 5
• If history of venous thromboembolism → Both copper and levonorgestrel IUDs are acceptable (Category 1-2), but copper IUD is preferred 5

Step 4: If patient declines IUD

• Recommend etonogestrel implant as second-line LARC option 1
• Counsel about unpredictable bleeding patterns and offer trial period 1

Step 5: If patient declines all LARCs

• Recommend progestin-only pills as third-line option, avoiding combined hormonal methods 1, 3
• Emphasize daily adherence requirements and consider setting phone reminders 1

Special Populations

Post-Bariatric Surgery Patients

• LARC methods (implants, IUDs) are first-line and unaffected by malabsorptive procedures 1
• All oral contraceptives should be avoided after bypass procedures due to unpredictable absorption 1, 3
• Contraception is mandatory for at least 12 months post-surgery to allow for weight stabilization before pregnancy 1

Immediate Postpartum Period

• Both levonorgestrel IUD and etonogestrel implant can be inserted immediately postpartum before hospital discharge 1
• Immediate postpartum LARC insertion removes barriers to care and prevents short interpregnancy intervals in high-risk women 1
• No effect on breastfeeding performance or infant health has been demonstrated with progestin-only LARCs 1

Common Pitfalls to Avoid

• Do not delay LARC insertion waiting for weight loss—contraception is safer than pregnancy at any weight, and obesity-related pregnancy complications are substantial 2
• Do not prescribe combined oral contraceptives to obese women with additional cardiovascular risk factors (hypertension, diabetes, smoking)—this creates unacceptable thrombotic risk 1, 4
• Do not assume IUD insertion will be difficult in obese women—success rates are equivalent across BMI categories 8
• Do not recommend DMPA to weight-conscious obese patients—it causes the most weight gain of any method 7
• Do not use BMI alone to deny access to any LARC method—obesity is not a contraindication to IUD or implant use 1, 2